Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 47, 2015, Pages E6525-E6534

  Yang, Yunan ^a,b   Hernandez, Reinier ^c   Rao, Jun ^b   Yin, Li ^b   Qu, Yazhuo ^b   Wu, Jinrong ^b   England, Christopher G ^c   Graves, Stephen A ^c   Lewis, Christina M ^c   Wang, Pu ^b   Meyerand, Mary E ^c   Nickles, Robert J ^c   Bian, Xiu Wu ^b   Cai, Weibo ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cancer stem cells; CD146; Epithelial mesenchymal transition; Glioblastoma multiforme; Positron emission tomography

Indexed keywords

CD146 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY YY 146; UNCLASSIFIED DRUG; COPPER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; CANCER CELL LINE; CANCER GRADING; CANCER SIZE; CANCER STEM CELL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SOLID TUMOR; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CELL CLONE; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSCRIPTION; GLIOMA; IMMUNOLOGY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PATHOLOGY; PROTEIN SYNTHESIS; SUBCUTANEOUS TISSUE; TIME FACTOR; TISSUE DISTRIBUTION; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD146; BRAIN NEOPLASMS; CELL LINE, TUMOR; CLONE CELLS; COPPER RADIOISOTOPES; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MICE, NUDE; NEOPLASM GRADING; NEOPLASTIC STEM CELLS; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BIOSYNTHESIS; SUBCUTANEOUS TISSUE; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948173342     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1502648112     Document Type: Article

References (36)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5-29.
2. Ostrom QT, et al. (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-oncol 15(Suppl 2): ii1-ii56.
3. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: A clinical review. JAMA 310(17):1842-1850.
4. Huse JT, Holland EC (2010) Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10(5):319-331.
5. Lehmann JM, Riethmüller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86(24):9891-9895.
6. Ouhtit A, et al. (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 1795(2):130-136.
7. Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330(2):150-162.
8. Zeng Q, et al. (2012) CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 109(4):1127-1132.
9. James ML, Gambhir SS (2012) A molecular imaging primer: Modalities, imaging agents, and applications. Physiol Rev 92(2):897-965.
10. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126-1136.
11. Jacobson O, Chen X (2013) Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging: Theranostic approaches to improve therapeutics. Pharmacol Rev 65(4):1214-1256.
12. Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48(6):932-945.
13. Rodda DJ, et al. (2005) Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 280(26):24731-24737.
14. Villarejo A, Cortés-Cabrera A, Molina-Ortíz P, Portillo F, Cano A (2014) Differential role of Snail1 and Snail2 zinc fingers in E-cadherin repression and epithelial to mesenchymal transition. J Biol Chem 289(2):930-941.
15. Yamazaki D, Kurisu S, Takenawa T (2009) Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. Oncogene 28(13):1570-1583.
16. Weller M, Stupp R, Hegi M, Wick W (2012) Individualized targeted therapy for glioblastoma: Fact or fiction? Cancer J 18(1):40-44.
17. McGary EC, et al. (2003) A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res 9(17):6560-6566.
18. Mills L, et al. (2002) Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62(17):5106-5114.
19. Frank RT, Aboody KS, Najbauer J (2011) Strategies for enhancing antibody delivery to the brain. Biochim Biophys Acta 1816(2):191-198.
20. Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K (2012) The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 33(5-6):579-589.
21. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY (2002) Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review). Oncol Rep 9(4):683-688.
22. Paganelli G, et al. (2006) Radioimmunotherapy of brain tumor. Neurol Res 28(5): 518-522.
23. Chen W (2007) Clinical applications of PET in brain tumors. J NuclMed 48(9):1468-1481.
24. Singh M, Ferrara N (2012) Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 30(7):648-657.
25. Sausville EA, Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66(7):3351-3354, discussion 3354.
26. Gaedicke S, et al. (2014) Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. Proc Natl Acad Sci USA 111(6):E692-E701.
27. Cruceru ML, Neagu M, Demoulin JB, Constantinescu SN (2013) Therapy targets in glioblastoma and cancer stem cells: Lessons from haematopoietic neoplasms. J Cell Mol Med 17(10):1218-1235.
28. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704-715.
29. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29(34):4741-4751.
30. Witta SE, et al. (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66(2): 944-950.
31. Guo Y, et al. (2011) Expression profile of embryonic stem cell-Associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 59(4):763-775.
32. Tyler B, et al. (2010) A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neurosurg 113(2):210-217.
33. Grivel JC, et al. (1993) Rapid induction of anti-idiotypic responses to unmodified monoclonal antibodies from syngeneic mice following primary immunization. J Immunol Methods 158(2):173-182.
34. Hong H, et al. (2011) Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 38(7):1335-1343.
35. Yang Y, et al. (2011) In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 38(11):2066-2076.
36. Shi Y, et al. (2014) Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res 20(7):1803-1813.